• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » CathVision closes $7.2M financing round for electrophysiology recording tech

CathVision closes $7.2M financing round for electrophysiology recording tech

August 17, 2022 By Sean Whooley

CathVision marketing image
[Image from CathVision]
Electrophysiology (EP) technology developer CathVision announced today that it secured $7.2 million in funding from existing investors.

Copenhagen, Denmark–based CathVision plans to use the funds to advance commercial operations for driving the adoption of its ECGenius system for EP recording. Additionally, funds will go toward developing artificial intelligence (AI)-powered analytic modules to provide electrophysiologists with automated analysis during cardiac ablation procedures.

“Our investors have witnessed the evolution of our company and technology in recent years,” Mads Matthiesen, CathVision CEO, said in a news release. “Reinvesting in the company demonstrates confidence in our innovation, ongoing development, and ability to advance adoption of the ECGenius System throughout the United States as we focus on empowering physicians to diagnose, characterize, and treat cardiac arrhythmias more effectively. We are expanding our sales team, building our U.S. presence, and furthering the development of analytic modules.”

What is the ECGenius system?

CathVision’s ECGenius system features a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms. The company said its technology offers a progression in the quality of cardiac signal acquisition. It’s also supposed to boost the accuracy of electrogram interpretation. The idea is to advance therapy support to help electrophysiologists improve the overall diagnosis and treatment of complex atrial arrhythmias, including AFib.

ECGenius picked up FDA 510(k) clearance in May. CathVision is currently offering the platform in a limited market release and has not confirmed when it will commence a wider release.

“Cardiac ablation is one of the fastest growing markets in healthcare; treatment efficiency and efficacy must improve for physicians to deliver the best possible care for patients with atrial fibrillation and other cardiac arrhythmias,” said Matthieu Bocquet, a founding partner at Lumine Capital. “CathVision’s modern and precise EP recording technology brings more clarity to physicians by delivering clear signals that can be accurately interpreted. This is a necessary step to improve treatment outcomes.”

Filed Under: Business/Financial News, Cardiovascular, Funding Roundup, Health Technology, Software / IT Tagged With: cathvision

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy